These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2145904)

  • 1. Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
    Hardy JR; Powles TJ; Judson IR; Sinnett HD; Ashley SE; Coombes RC; Ellin CL
    Eur J Cancer; 1990; 26(7):824-7. PubMed ID: 2145904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
    Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
    Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
    Wander HE; Nagel GA; Blossey HC; Kleeberg U
    Cancer; 1986 Nov; 58(9):1985-9. PubMed ID: 2944573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
    Powles TJ; Gordon C; Coombes RC
    Cancer Res; 1982 Aug; 42(8 Suppl):3458s-3460s. PubMed ID: 7044528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide.
    Brufman G; Isacson R; Haim N; Gez E; Sulkes A
    Oncology; 1994; 51(3):258-61. PubMed ID: 8196908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
    Milsted R; Habeshaw T; Kaye S; Sangster G; Macbeth F; Campbell-Ferguson J; Smith D; Calman K
    Cancer Chemother Pharmacol; 1985; 14(3):272-3. PubMed ID: 3888433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental combined hormone therapy on human breast carcinomas serially transplanted into nude mice.
    Fukutomi T; Kubota T; Ikeda T; Isobe Y; Kikuyama S; Shimada A; Nakamura A; Nishiumi T; Enomoto K; Ishibiki K
    Jpn J Cancer Res; 1986 Jan; 77(1):92-7. PubMed ID: 2937762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer.
    Petru E; Schmähl D
    Klin Wochenschr; 1987 Oct; 65(20):959-66. PubMed ID: 2963170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive hormonal therapy in women with advanced breast cancer.
    Ingle JN
    Cancer; 1984 Feb; 53(3 Suppl):766-77. PubMed ID: 6229323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
    Grem JL; Falkson G; Love RR; Tormey DC
    Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
    Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
    Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
    Horton J; Knuiman M; Keller AM; Vogel H; Gale KE; Hahn RG; Rosenbluth RJ; Tormey DC
    Cancer; 1987 Nov; 60(9):2137-40. PubMed ID: 3440224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
    Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
    J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
    Nemoto T; Patel JK; Rosner D; Dao TL; Halvorson H
    J Surg Oncol; 1989 Aug; 41(4):226-9. PubMed ID: 2526907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
    Pronzato P; Rubagotti A; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso M; Gallotti P; Monzeglio C; Rosso R
    Am J Clin Oncol; 1993 Dec; 16(6):522-5. PubMed ID: 8256770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination of tamoxifen and high dose medroxyprogesterone acetate: therapeutic and endocrine effects in postmenopausal advanced breast cancer patients.
    Gasparini G; Canobbio L; Galligioni E; Fassio T; Brema F; Crivellari D; Villalta D; Di Fronzo G; Talamini R; Monfardini S
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1451-9. PubMed ID: 2960532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.